Covered recipient · General Payments record
SHACHAR PELES
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$54,323.37
220 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,275.00 | 20 |
| Travel and Lodging | $5,003.10 | 13 |
| Food and Beverage | $4,030.09 | 185 |
| Education | $15.18 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SHACHAR PELES
NPI 1568412930 · CMS profile ID 252607
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
PALM SPRINGS, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1568412930?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SHACHAR PELES, NPI 1568412930, CMS profile ID 252607. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568412930?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). SHACHAR PELES, NPI 1568412930, CMS profile ID 252607. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568412930?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- SHACHAR PELES, NPI 1568412930, CMS profile ID 252607, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1568412930?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
220 matching records · $54,323.37 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 220.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Celgene Corporation | $770.00 | 04/25/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672838887 | CMS |
| Celgene Corporation | $1,977.50 | 04/25/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672853855 | CMS |
| Janssen Biotech, Inc. | $3.22 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658641701 | CMS |
| Seattle Genetics, Inc. | $2.88 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678797741 | CMS |
| Seattle Genetics, Inc. | $3.05 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678797743 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.65 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651308871 | CMS |
| EISAI INC. | $14.39 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697004079 | CMS |
| PFIZER INC. | $14.20 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673293761 | CMS |
| Genentech USA, Inc. | $18.24 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681251741 | CMS |
| Seattle Genetics, Inc. | $22.47 | 04/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678797735 | CMS |
| Celgene Corporation | $137.06 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672845561 | CMS |
| Genentech USA, Inc. | $10.88 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681146637 | CMS |
| Lilly USA, LLC | $15.11 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658148631 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $639.75 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697371673 | CMS |
| Incyte Corporation | $15.63 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666273981 | CMS |
| Celgene Corporation | $1,155.00 | 04/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672837990 | CMS |
| Celgene Corporation | $840.56 | 04/02/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673014597 | CMS |
| Celgene Corporation | $1,977.50 | 04/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673014603 | CMS |
| Gilead Sciences, Inc. | $12.97 | 04/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681581907 | CMS |
| PFIZER INC. | $15.94 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673297737 | CMS |
| PFIZER INC. | $0.88 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673772517 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,620.00 | 03/30/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697371645 | CMS |
| Seattle Genetics, Inc. | $1,200.00 | 03/29/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678797773 | CMS |
| Shire North American Group Inc | $19.86 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637894553 | CMS |
| Heron Therapeutics, Inc. | $15.42 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674510357 | CMS |
| Merck Sharp & Dohme Corporation | $14.03 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695392385 | CMS |
| Novartis Pharmaceuticals Corporation | $15.00 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659922421 | CMS |
| Janssen Biotech, Inc. | $1.19 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658641693 | CMS |
| Janssen Biotech, Inc. | $17.05 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658641697 | CMS |
| Novartis Pharmaceuticals Corporation | $16.83 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659922423 | CMS |
| Celgene Corporation | $119.09 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672867593 | CMS |
| Amgen Inc. | $7.44 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663033223 | CMS |
| Amgen Inc. | $23.05 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663033237 | CMS |
| Amgen Inc. | $23.05 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663033243 | CMS |
| Helsinn Therapeutics (U.S.), Inc. | $12.28 | 03/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655947063 | CMS |
| AbbVie, Inc. | $16.16 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648019127 | CMS |
| Janssen Biotech, Inc. | $14.50 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658641688 | CMS |
| Celgene Corporation | $1,977.50 | 03/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672768231 | CMS |
| Celgene Corporation | $770.00 | 03/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672797635 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.45 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673455117 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.89 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697384759 | CMS |
| Genentech USA, Inc. | $16.23 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681262369 | CMS |
| Alexion Pharmaceuticals, Inc. | $16.95 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695601809 | CMS |
| Janssen Biotech, Inc. | $17.07 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658641681 | CMS |
| Janssen Biotech, Inc. | $1.56 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658641685 | CMS |
| Astellas Pharma US Inc | $12.88 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655726691 | CMS |
| Celgene Corporation | $103.20 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672773447 | CMS |
| Genentech USA, Inc. | $12.28 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681163967 | CMS |
| Seattle Genetics, Inc. | $15.03 | 02/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678797731 | CMS |
| Spectrum Pharmaceuticals Inc. | $12.89 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 639801171 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,523.50 | 2 |
| PY2025 | Principal investigator | $878,753.65 | 202 |
| PY2024 | Principal investigator | $851,406.62 | 209 |
| PY2023 | Principal investigator | $892,313.76 | 260 |
| PY2022 | Recipient | $4,500.00 | 1 |
| PY2022 | Principal investigator | $545,008.17 | 92 |
| PY2021 | Principal investigator | $202,816.75 | 86 |
| PY2020 | Principal investigator | $203,140.61 | 56 |
| PY2019 | Principal investigator | $190,691.85 | 48 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
204 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | F. Hoffmann-La Roche AG | $939.17 | 12/10/2025 | Covered Recipient Physician | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211538857 |
| Principal investigator 1 | Acerta Pharma LLC | $650.00 | 12/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185541038 |
| Recipient | F. Hoffmann-La Roche AG | $584.33 | 12/08/2025 | Covered Recipient Physician | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211538862 |
| Principal investigator 1 | Epizyme, Inc. | $411.25 | 11/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283461 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,466.00 | 11/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1235993851 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $9,795.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664384 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664390 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664408 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664412 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,000.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664414 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664424 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 11/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664434 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $19,135.48 | 11/06/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1235993853 |
| Principal investigator 1 | Genentech, Inc. | $156.00 | 10/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652369 |
| Principal investigator 1 | Genentech, Inc. | $1,939.00 | 10/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652380 |
| Principal investigator 1 | ABBVIE INC. | $2,265.00 | 10/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202514391 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 09/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664406 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,897.50 | 09/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664420 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 09/26/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664430 |
| Principal investigator 1 | ABBVIE INC. | $1,045.00 | 09/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202507505 |
| Principal investigator 1 | ABBVIE INC. | $3,913.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202504811 |
| Principal investigator 1 | ABBVIE INC. | $7,462.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202504901 |
| Principal investigator 1 | Genentech, Inc. | $1,058.40 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Polarix | No dispute reported | 06/30/2026 | 1211649222 |
| Principal investigator 1 | Celgene Corporation | $43,565.97 | 08/13/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222305646 |
| Principal investigator 1 | Epizyme, Inc. | $4,200.00 | 08/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283435 |
| Principal investigator 1 | ABBVIE INC. | $1,045.00 | 08/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202502056 |
| Principal investigator 1 | Epizyme, Inc. | $4,200.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283105 |
| Principal investigator 1 | Epizyme, Inc. | $35.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283111 |
| Principal investigator 1 | Epizyme, Inc. | $35.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283115 |
| Principal investigator 1 | Epizyme, Inc. | $37.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283119 |
| Principal investigator 1 | Epizyme, Inc. | $37.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283137 |
| Principal investigator 1 | Epizyme, Inc. | $125.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283153 |
| Principal investigator 1 | Epizyme, Inc. | $37.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283155 |
| Principal investigator 1 | Epizyme, Inc. | $35.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283157 |
| Principal investigator 1 | Epizyme, Inc. | $35.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283159 |
| Principal investigator 1 | Epizyme, Inc. | $4,200.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283163 |
| Principal investigator 1 | Epizyme, Inc. | $37.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283203 |
| Principal investigator 1 | Epizyme, Inc. | $37.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283205 |
| Principal investigator 1 | Epizyme, Inc. | $37.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283207 |
| Principal investigator 1 | Epizyme, Inc. | $35.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283209 |
| Principal investigator 1 | Epizyme, Inc. | $37.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283211 |
| Principal investigator 1 | Epizyme, Inc. | $35.00 | 07/28/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283221 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 07/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652081 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 07/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202499496 |
| Principal investigator 1 | Genentech, Inc. | $6,170.00 | 07/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652115 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 07/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651762 |
| Principal investigator 1 | Genentech, Inc. | $81.00 | 07/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651945 |
| Principal investigator 1 | Genentech, Inc. | $8,887.00 | 07/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652142 |
| Principal investigator 1 | Genentech, Inc. | $375.00 | 07/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652228 |
| Principal investigator 1 | Epizyme, Inc. | $4,200.00 | 07/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283107 |
| Principal investigator 1 | ABBVIE INC. | $1,045.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202494159 |
| Principal investigator 1 | Genentech, Inc. | $39.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651684 |
| Principal investigator 1 | Genentech, Inc. | $688.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651739 |
| Principal investigator 1 | Genentech, Inc. | $195.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651752 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651796 |
| Principal investigator 1 | Genentech, Inc. | $155.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651817 |
| Principal investigator 1 | Genentech, Inc. | $6,014.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651855 |
| Principal investigator 1 | Genentech, Inc. | $155.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651878 |
| Principal investigator 1 | Genentech, Inc. | $49.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651914 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651948 |
| Principal investigator 1 | Genentech, Inc. | $65.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651961 |
| Principal investigator 1 | Genentech, Inc. | $51.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652015 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652119 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652159 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652232 |
| Principal investigator 1 | Genentech, Inc. | $54.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652257 |
| Principal investigator 1 | Genentech, Inc. | $688.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652285 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 07/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211652294 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 07/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202493789 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 06/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664402 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $9,795.00 | 06/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664404 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 06/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664426 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 06/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664432 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664392 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664416 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664428 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664436 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664438 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664452 |
| Principal investigator 1 | ABBVIE INC. | $566.25 | 06/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202490319 |
| Principal investigator 1 | AstraZeneca UK Limited | $8,577.00 | 06/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1185541034 |
| Principal investigator 1 | ABBVIE INC. | $1,045.00 | 06/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202489823 |
| Principal investigator 1 | Celgene Corporation | $27,364.00 | 06/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1222305526 |
| Principal investigator 1 | Genentech, Inc. | $125.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651012 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651119 |
| Principal investigator 1 | Genentech, Inc. | $45.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651155 |
| Principal investigator 1 | Genentech, Inc. | $63.75 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651208 |
| Principal investigator 1 | Genentech, Inc. | $25.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651213 |
| Principal investigator 1 | Genentech, Inc. | $56.25 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651245 |
| Principal investigator 1 | Genentech, Inc. | $63.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651303 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651323 |
| Principal investigator 1 | Genentech, Inc. | $63.75 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651346 |
| Principal investigator 1 | Genentech, Inc. | $101.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651351 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651355 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651392 |
| Principal investigator 1 | Genentech, Inc. | $80.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651427 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651536 |
| Principal investigator 1 | Genentech, Inc. | $80.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651588 |
| Principal investigator 1 | Genentech, Inc. | $63.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651600 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 05/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651603 |
| Principal investigator 1 | Celgene Corporation | $20,000.00 | 05/21/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute Llc | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1222306821 |
| Principal investigator 1 | Genentech, Inc. | $44.00 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650973 |
| Principal investigator 1 | Genentech, Inc. | $155.00 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651009 |
| Principal investigator 1 | Genentech, Inc. | $63.75 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651031 |
| Principal investigator 1 | Genentech, Inc. | $63.75 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651065 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651298 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651387 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651083 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651188 |
| Principal investigator 1 | Celgene Corporation | $16,900.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute Llc | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1222306703 |
| Principal investigator 1 | Epizyme, Inc. | $100.00 | 05/07/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283087 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650923 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650956 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651133 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651148 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651482 |
| Principal investigator 1 | Genentech, Inc. | $63.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651485 |
| Principal investigator 1 | Genentech, Inc. | $63.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651521 |
| Principal investigator 1 | ABBVIE INC. | $1,045.00 | 05/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202481999 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 05/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650979 |
| Principal investigator 1 | Genentech, Inc. | $56.25 | 05/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651035 |
| Principal investigator 1 | Genentech, Inc. | $5,441.00 | 05/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651073 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 05/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651142 |
| Principal investigator 1 | Genentech, Inc. | $56.25 | 05/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651341 |
| Principal investigator 1 | Celgene Corporation | $42,699.33 | 04/23/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222305520 |
| Principal investigator 1 | Genentech, Inc. | $14,296.00 | 04/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211651434 |
| Principal investigator 1 | ABBVIE INC. | $637.00 | 04/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202475993 |
| Principal investigator 1 | Eli Lilly and Company | $907.15 | 04/08/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187883696 |
| Principal investigator 1 | Eli Lilly and Company | $976.45 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | No dispute reported | 06/30/2026 | 1187889042 |
| Principal investigator 1 | ABBVIE INC. | $1,183.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202474756 |
| Principal investigator 1 | ABBVIE INC. | $20,020.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202474760 |
| Principal investigator 1 | ABBVIE INC. | $2,912.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202474764 |
| Principal investigator 1 | ABBVIE INC. | $1,365.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202474768 |
| Principal investigator 1 | ABBVIE INC. | $1,274.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202474781 |
| Principal investigator 1 | ABBVIE INC. | $1,274.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202474785 |
| Principal investigator 1 | ABBVIE INC. | $16,562.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202474789 |
| Principal investigator 1 | ABBVIE INC. | $1,638.00 | 04/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202474797 |
| Principal investigator 1 | Celgene Corporation | $39,415.00 | 04/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1222305610 |
| Principal investigator 1 | ABBVIE INC. | $1,045.00 | 04/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202473544 |
| Principal investigator 1 | Epizyme, Inc. | $4,200.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283021 |
| Principal investigator 1 | Epizyme, Inc. | $4,200.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283033 |
| Principal investigator 1 | Epizyme, Inc. | $86.00 | 04/02/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184283065 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202467977 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,516.71 | 03/25/2025 | Non-covered Recipient Entity Florida Cancer Specialists | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1235997357 |
| Principal investigator 1 | ABBVIE INC. | $1,729.00 | 03/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202464004 |
| Principal investigator 1 | ABBVIE INC. | $4,186.00 | 03/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202464008 |
| Principal investigator 1 | ABBVIE INC. | $2,093.00 | 03/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202464012 |
| Principal investigator 1 | ABBVIE INC. | $819.00 | 03/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202464020 |
| Principal investigator 1 | ABBVIE INC. | $2,275.00 | 03/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202464056 |
| Principal investigator 1 | ABBVIE INC. | $4,186.00 | 03/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202464059 |
| Principal investigator 1 | ABBVIE INC. | $2,093.00 | 03/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202464121 |
| Principal investigator 1 | ABBVIE INC. | $3,640.00 | 03/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202464125 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $50.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664394 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $19,590.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664396 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $43.75 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664400 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $22,851.25 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664410 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664418 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664440 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664444 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $7,346.25 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664454 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $500.00 | 03/17/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664456 |
| Principal investigator 1 | ABBVIE INC. | $7,007.00 | 03/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202462984 |
| Principal investigator 1 | ABBVIE INC. | $8,281.00 | 03/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202463024 |
| Principal investigator 1 | ABBVIE INC. | $11,921.00 | 03/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202463079 |
| Principal investigator 1 | ABBVIE INC. | $2,002.00 | 03/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202463083 |
| Principal investigator 1 | ABBVIE INC. | $7,007.00 | 03/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202463182 |
| Principal investigator 1 | ABBVIE INC. | $1,045.00 | 03/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202456683 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,245.14 | 02/25/2025 | Non-covered Recipient Entity Florida Cancer Specialists | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1235997355 |
| Principal investigator 1 | Genentech, Inc. | $63.00 | 02/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650596 |
| Principal investigator 1 | ABBVIE INC. | $8,535.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202445809 |
| Principal investigator 1 | Genentech, Inc. | $2,067.00 | 01/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Polarix | No dispute reported | 06/30/2026 | 1211649208 |
| Principal investigator 1 | ABBVIE INC. | $91.00 | 01/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202443239 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/30/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664380 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/30/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664422 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/30/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664442 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/30/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664446 |
| Principal investigator 1 | AstraZeneca UK Limited | $3,200.00 | 01/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1185541040 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664382 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664386 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664388 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664398 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664448 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,500.00 | 01/16/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, LLC | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246664450 |
| Principal investigator 1 | Genentech, Inc. | $10,684.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650335 |
| Principal investigator 1 | Eli Lilly and Company | $62,406.25 | 01/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187889036 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,723.75 | 01/10/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Nave Subjec | No dispute reported | 06/30/2026 | 1235993849 |
| Principal investigator 1 | Eli Lilly and Company | $815.07 | 01/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187889662 |
| Principal investigator 1 | Acerta Pharma LLC | $5,017.00 | 01/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185541036 |
| Principal investigator 1 | Eli Lilly and Company | $96,560.26 | 01/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187889034 |
| Principal investigator 1 | Eli Lilly and Company | $80,066.69 | 01/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | No dispute reported | 06/30/2026 | 1187889466 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650345 |
| Principal investigator 1 | Genentech, Inc. | $125.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650376 |
| Principal investigator 1 | Genentech, Inc. | $63.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650391 |
| Principal investigator 1 | Genentech, Inc. | $156.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650683 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650715 |
| Principal investigator 1 | Genentech, Inc. | $80.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650766 |
| Principal investigator 1 | Genentech, Inc. | $125.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650770 |
| Principal investigator 1 | Genentech, Inc. | $1,376.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650775 |
| Principal investigator 1 | Genentech, Inc. | $81.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650778 |
| Principal investigator 1 | Genentech, Inc. | $158.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650785 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | No dispute reported | 06/30/2026 | 1211650841 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 01/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202435766 |
| Principal investigator 1 | ABBVIE INC. | $728.00 | 01/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202435813 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $18,682.00 | 01/01/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190307947 |